Articles by Sofia Alvarez
Vertex CASGEVY Gene Therapy Reaches 60,000+ Eligible Patients Across 10 Countries as Q1 2026 Results Show Global Expansion
Vertex's CASGEVY, the first approved CRISPR gene therapy, now serves 60,000+ eligible sickle cell disease and beta thalassemia patients across 10 countries.
Novelty Nobility Expands AGC Biologics Partnership for Bispecific Antibody Manufacturing
South Korean biotech Novelty Nobility expands manufacturing deal with AGC Biologics to advance bispecific antibody candidate through GMP production in Japan.
Smartee Denti-Technology Advances Mandibular Repositioning Technology at European Aligner Society Congress 2026
Smartee Denti-Technology presents breakthrough mandibular repositioning innovations and European expansion strategy at EAS Congress 2026 in Brussels.
MHRA Drug Approval Divergence: UK vs EU Market Access & Investment Impact
This article delves into the differences in MHRA drug approval processes for [Drug Name] in [Indication], highlighting their effects on market access and investment strategies in the UK and EU.
FDA Approves Auvelity for MDD: Axsome Therapeutics' New Antidepressant
The FDA has approved Auvelity (dextromethorphan and bupropion) from Axsome Therapeutics for the treatment of major depressive disorder (MDD) in adults. This marks a significant advancement in MDD therapy with a new mechanism of action.
SynbioTech Unveils Microbiome-Based Platform for Women's Healthy Aging at Vitafoods Europe 2026
Taiwan-based SynbioTech presents clinical evidence for probiotic solutions targeting women's muscle maintenance, gut health, and metabolic balance at Vitafoods.
SetPoint Medical Begins Multiple Sclerosis Trial for Setpoint System Neuroimmune Therapy
SetPoint Medical enrolls first patients in pilot study testing Setpoint System for relapsing-remitting multiple sclerosis treatment with FDA approval.
EU Clinical Trials Regulation Impact on Rare Disease Drug Development
This article examines the impact of the EU Clinical Trials Regulation on the development of drugs for rare diseases, focusing on challenges and opportunities for treatments.
Henlius and Organon's POHERDY Becomes First Pertuzumab Biosimilar Approved in Europe
European Commission approves POHERDY as first pertuzumab biosimilar in Europe, offering cost-effective alternative to PERJETA for breast cancer treatment.
Real-World Evidence Oncology Drugs: EMA vs MHRA Regulatory Approaches
This article compares the EMA and MHRA's regulatory frameworks for real-world evidence in oncology drugs, focusing on their implications for cancer treatment.
EMA Conditional Marketing Authorization: Impact on Oncology Patient Access in EU
This article examines the impact of EMA Conditional Marketing Authorization on improving access to innovative oncology drugs, such as XYZ, for patients in the EU.
EU Pharmaceutical Legislation: Impact on Orphan Drug Market Exclusivity
This article examines the implications of recent EU pharmaceutical legislation on the market exclusivity of orphan drugs, crucial for rare disease therapies.
Brii Bio's Elebsiran Shows Durable Hepatitis B Control in APASL 2026 Cross-Study Analysis
Brii Bio's elebsiran combined with pegylated interferon demonstrates sustained HBsAg loss and favorable off-treatment outcomes in hepatitis B patients.
CAR-T Cell Therapy Japan: Regulatory Insights & Clinical Trial Landscape
This article delves into CAR-T cell therapy in Japan, highlighting regulatory frameworks and the evolving clinical trial landscape for hematologic malignancies.
EMA Issues Positive Opinion for Viatris' Palbociclib Generic Cancer Treatment
European Medicines Agency issues positive opinion for Viatris' generic palbociclib, potentially expanding access to this important breast cancer treatment.
Aetna Standardizes 88% of Prior Authorization Volume, Exceeds Industry Commitments for Healthcare Access
Aetna announces 88% prior authorization standardization, surpassing industry goals while maintaining fewest medical service requirements among national health plans.
RNA Therapy Clinical Trials Market Reaches $3.4 Billion as Personalized Medicine Drives Growth Through 2035
RNA therapy clinical trials market hits $3.4B driven by delivery advances, rare disease funding, and personalized medicine growth through 2035.
PMDA SAKIGAKE Designation: Expedited Approval & Market Impact in Japan
Explore the significance of PMDA SAKIGAKE Designation in expediting approval processes and its impact on the market for drugs like XYZ in Japan.
Clinical Trial Data Sharing in MEA: Regional Registry Integration Progress 2026
This article examines the advancements in clinical trial data sharing and regional registry integration for drug XYZ in the MEA region as of 2026.
Center for Cancer and Blood Disorders Launches CAR T-Cell Therapy Program in Maryland, Expanding Community Access
CCBD becomes first Maryland community oncology practice to offer FDA-approved CAR T-cell therapy, significantly expanding patient access in the region.